According to a survey conducted in 2021, 94 percent of oncologists indicated being very or somewhat familiar with biosimilars. The percentage of physicians who are "very familiar" with biosimilars was highest among diabetes specialists.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Amgen. (October 31, 2022). Familiarity with biosimilars among specialized physicians in the U.S. as of 2021 [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 20, 2026, from /statistics/1088408/physicians-biosimilars-familiarity-us/
Amgen. "Familiarity with biosimilars among specialized physicians in the U.S. as of 2021." Chart. October 31, 2022. ÌÇÐÄÆƽâ°æ. Accessed July 20, 2026. /statistics/1088408/physicians-biosimilars-familiarity-us/
Amgen. (2022). Familiarity with biosimilars among specialized physicians in the U.S. as of 2021. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 20, 2026. /statistics/1088408/physicians-biosimilars-familiarity-us/
Amgen. "Familiarity with Biosimilars among Specialized Physicians in The U.S. as of 2021." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 31 Oct 2022, /statistics/1088408/physicians-biosimilars-familiarity-us/
Amgen, Familiarity with biosimilars among specialized physicians in the U.S. as of 2021 ÌÇÐÄÆƽâ°æ, /statistics/1088408/physicians-biosimilars-familiarity-us/ (last visited July 20, 2026)
Familiarity with biosimilars among specialized physicians in the U.S. as of 2021 [Graph], Amgen, October 31, 2022. [Online]. Available: /statistics/1088408/physicians-biosimilars-familiarity-us/
